By Fineline Cube China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its next-generation epidermal growth factor receptor (EGFR) inhibitor sunvozertinib (DZD9008) combined with bevacizumab in locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation.
Ongoing International Clinical Study
Sunvozertinib, being developed to treat EGFR exon 20 insertion mutation NSCLC, is currently undergoing an international multi-center single-arm pivotal Phase II clinical study. Patient enrollment is underway in sites in China, the US, South Korea, Australia, Japan, and other countries. The latest data presented at this year’s World Conference on Lung Cancer (WCLC) showed that the best overall response rate (ORR) was 52.4%, while in patients with baseline brain metastasis, the best ORR reached 44%. Additionally, the safety profile of the drug was reported to be good.-Fineline Info & Tech